These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30084546)

  • 1. Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.
    Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ
    CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):549-561. PubMed ID: 30084546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.
    Zhu X; Straubinger RM; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):477-96. PubMed ID: 26252969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated
    Wang X; Niu J; Li J; Shen X; Shen S; Straubinger RM; Qu J
    Mol Cell Proteomics; 2018 Apr; 17(4):655-671. PubMed ID: 29358341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.
    Zhu X; Trueman S; Straubinger RM; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):733-746. PubMed ID: 30069744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways.
    Miao X; Koch G; Shen S; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
    J Pharm Sci; 2024 Jan; 113(1):235-245. PubMed ID: 37918792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K; Fidler IJ
    Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.
    Bu HQ; Luo J; Chen H; Zhang JH; Li HH; Guo HC; Wang ZH; Lin SZ
    Int J Oncol; 2012 Sep; 41(3):949-58. PubMed ID: 22710877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
    Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
    Kazim S; Malafa MP; Coppola D; Husain K; Zibadi S; Kashyap T; Crochiere M; Landesman Y; Rashal T; Sullivan DM; Mahipal A
    Mol Cancer Ther; 2015 Jul; 14(7):1570-81. PubMed ID: 25934708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
    Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
    J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
    Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
    Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
    Ricciardi S; Mey V; Nannizzi S; Pasqualetti G; Crea F; Del Tacca M; Danesi R
    Chemotherapy; 2010; 56(4):303-12. PubMed ID: 20714148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
    Ali S; Ahmad A; Banerjee S; Padhye S; Dominiak K; Schaffert JM; Wang Z; Philip PA; Sarkar FH
    Cancer Res; 2010 May; 70(9):3606-17. PubMed ID: 20388782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer.
    Lee SH; Ryu JK; Lee KY; Woo SM; Park JK; Yoo JW; Kim YT; Yoon YB
    Cancer Lett; 2008 Jan; 259(1):39-49. PubMed ID: 17967505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
    Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
    J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol.
    Paik WH; Kim HR; Park JK; Song BJ; Lee SH; Hwang JH
    Anticancer Res; 2013 Apr; 33(4):1473-81. PubMed ID: 23564788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.